Determining the optimal protocol for measuring an albuminuria class transition in clinical trials in diabetic kidney disease

Journal of the American Society of Nephrology

Volumn 27, Issue 11, 2016, Pages 3405-3412

  Kröpelin, Tobias F ^a   De Zeeuw, Dick ^a   Remuzzi, Giuseppe ^b,c   Bilous, Rudy ^d   Parving, Hans Henrik ^e   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; TRANDOLAPRIL; VERAPAMIL;

ALBUMINURIA; ALBUMINURIA CLASS TRANSITION; ARTICLE; CLINICAL OUTCOME; CREATININE BLOOD LEVEL; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RENAL SYSTEM PARAMETERS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; URINE LEVEL; URINE SAMPLING; ADULT; AGED; CLASSIFICATION; CLINICAL PROTOCOL; DIABETIC NEPHROPATHY; MIDDLE AGED; STANDARDS; URINALYSIS; URINE;

ADULT; AGED; ALBUMINURIA; CLINICAL PROTOCOLS; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; URINALYSIS;

EID: 85017286854     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015101150     Document Type: Article

References (16)

1. Roscioni SS, Lambers Heerspink HJ, de Zeeuw D: Microalbuminuria: Target for renoprotective therapy PRO. Kidney Int 86: 40-49, 2014
2. Lambers Heerspink HJ, Gansevoort RT: Albuminuria is an appropriate therapeutic target in patients with CKD: The pro view. Clin J Am Soc Nephrol 10: 1079-1088, 2015
3. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl JMed 345: 870-878, 2001
4. BENEDICTGroup: The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics. Control Clin Trials 24: 442-461, 2003
5. Chaturvedi N, Sjoelie AK, Svensson A; DIRECT Programme Study Group: The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. J Renin Angiotensin Aldosterone Syst 3: 255-261, 2002
6. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA: Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): Rationale and study design. Nephrol Dial Transplant 24: 1663-1671, 2009
7. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group: Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30: 1577-1578, 2007
8. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S,Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G; ROADMAP Trial Investigators: Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl JMed 364: 907-917, 2011
9. Smulders YM, Slaats EH, Rakic M, Smulders FT, Stehouwer CD, Silberbusch J: Short-term variability and sampling distribution of various parameters of urinary albumin excretion in patients with noninsulin-dependent diabetes mellitus. J Lab Clin Med 132: 39-46, 1998
10. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJL, de Jong PE, Gansevoort R: First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 20: 436-443, 2009
11. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl JMed 351: 1941-1951, 2004
12. Bilous R, Chaturvedi N, Sjlie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH: Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: Three randomized trials. Ann Intern Med 151: 11-20, 2009
13. Parving H-H, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators: Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). J Renin Angiotensin Aldosterone Syst 13: 387-393, 2012
14. Viberti G, Mogensen CE, Groop LC, Pauls JF; European Microalbuminuria Captopril Study Group: Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275-279, 1994
15. Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ: Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy. Clin J Am Soc Nephrol 10: 410-416, 2015
16. Parving H-H, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, NicolaidesM, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl JMed 367: 2204-2213, 2012